Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models

Placenta

Volumn 32, Issue 7, 2011, Pages 531-534

  Ledon N ^a   Casaco A ^a   Casanova, E ^b   Beausoleil, I ^a  

^a Center for Molecular Immunology   (Cuba)

^b Centro de Isotopos   (Cuba)

Author keywords

Binding assay; Cetuximab; EGF receptor; Nimotuzumab; Placenta

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; FEMALE; HAPLORHINI; HUMAN; HUMAN TISSUE; LIGAND BINDING; MACACA FASCICULARIS; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RABBIT; RAT; RECEPTOR BINDING;

ANIMALS; ANTIBODIES, MONOCLONAL; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; MACACA FASCICULARIS; MICE; MICROSOMES; MODELS, ANIMAL; PLACENTA; PREGNANCY; RABBITS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECIES SPECIFICITY;

EID: 79958167185     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2011.04.008     Document Type: Article

References (38)

1. M.E. Arteaga, N. Ledon, A. Casaco, B. Pardo, M. García, and M. Boleda Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab Cancer Biology and Therapeutics 6 2007 1390 1395 (Pubitemid 351590348)
2. M.E. Arteaga-Perez, M. Maceira, A. Casaco, O. Hernandez-Sosa, A.M. Bada-Barro, and A. Leon-Goni Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys Human Experimental Toxicology 23 2004 219 227 (Pubitemid 38807666)
3. G.T. Baxter Hurel: an in vivo-surrogate assay platform for cell-based studies ATLA 37 S1 2009 11 18
4. N. Bhogal, and R. Combes TGN1412. Time to change the paradigm for the testing of new pharmaceuticals ATLA 34 2006 225 239 (Pubitemid 43844405)
5. R.A. Coleman Drug discovery and development tomorrow - changing the mindset ATLA 37 S1 2009 1 4
6. T. Crombet, M. Osorio, T. Cruz, C. Roca, R. del Castillo, and R. Mon Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients Journal of Clinical Oncology 22 2004 1646 1654 (Pubitemid 41079803)
7. EMEA. Avastin: EPAR - procedural steps taken and scientific information after authorisation; 2009. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000582/WC500029262.pdf [last accessed 19.03.10].
8. EMEA. Erbitux INN Cetuximab; 2009. Available at: http://www.ema.europa. eu/humandocs/PDFs/EPAR/erbitux/089404en6.pdf [last accessed 19.03.10].
9. S. Forsberg, A. Ostman, and O. Rollman Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase Archives of Dermatological Research 300 2008 505 516
10. G. Garrido, I. Tikhomirov, A. Rabasa, E. Yang, E. Gracia, and N. Iznaga Bivalent binding by intermediate affinity of nimotuzumab. A contribution to explain antibody clinical profile Cancer Biology & Therapy 11 2011 1 10
11. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clinical Cancer Research 1 1995 1311 1318
12. B. Groner, C. Hartmann, and W. Wels Therapeutic antibodies Current Molecular Medicine 4 2004 539 547 (Pubitemid 38961197)
13. A. Gruaz-Guyon, O. Raguin, and J. Barbet Recent advances in pretargeted radioimmunotherapy Current Medicinal Chemistry 12 2005 319 338 (Pubitemid 40305623)
14. W.M. Hunter, and F.C. Greenwood Preparation of iodine 131 labelled human growth hormone of high specific activity Nature 194 1962 495 496
15. ICH. Harmonised tripartite guideline preclinical safety evaluation of biotechnology-derived pharmaceuticals S6; 1996. Available at: www.emea.europa.eu/pdfs/human/ich/030295en.pdf [accessed 17.04.10].
16. N. Iznaga-Escobar, I.L. Ramirez, J.C. Izquierdo, L. Suárez, D. Morales, and R. Pérez-Rodríguez 188Re-labeled anti-epidermal growth factor receptor humanized monoclonal antibody h-R3: labeling conditions, in vitro and in vivo stability Methods & Findings in Experimental & Clinical Pharmacology 25 2003 703 711 (Pubitemid 38089621)
17. E. Kang, M. Oh, S. Lee, T.Y. Kim, S.H. Kim, and N. Gotoh EGFR phosphorylation dependent formation of cell-cell contacts by Ras/Erks cascade inhibition Biochimica et Biophysica Acta 1773 2007 833 843 (Pubitemid 46839139)
18. M. Keese, R.J. Magdeburg, T. Herzog, T. Hasenberg, M. Offterdinger, and R. Pepperkok Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues Journal of Biological Chemistry 280 2005 27826 27831 (Pubitemid 41076898)
19. W. Kells-Boland, and G. Bebb Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity Expert Opinion on Biological Therapy 9 2009 1199 1206
20. S.J. Kennel, L.J. Foote, P.K. Lankford, M. Jonson, T. Mitchell, and G.R. Braslawsky Direct binding of radioiodinated monoclonal antibody to tumor cells: significance of antibody purity and affinity for drug targeting or tumor imaging Hybridoma 2 1983 297 306
21. A. Knight Animal experiments scrutinized: some systemic reviews have demonstrated poor human clinical and toxicological utility ALTEX 24 2007 320 325
22. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311 (Pubitemid 40544648)
23. D.H. Lowry Protein measurement with the Folin phenol reagent Journal of Biological Chemistry 193 1951 265 267
24. A. Macías, R. Perez, and A. Lage Estudios sobre el factor de crecimiento epidérmico (EGF) I. Expresión del receptor en el cáncer mamario humano Interferón y biotecnología 2 1985 27 40
25. C. Mateo, J. Lombardero, E. Moreno, A. Morales, G. Bombino, and J. Coloma Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity Hybridoma 19 2000 463 471 (Pubitemid 32015237)
26. J. Mendelsohn, and J. Baselga Epidermal growth factor receptor targeting in cancer Seminars in Oncology 33 2006 369 385 (Pubitemid 44142736)
27. NCBI/BLAST/blastn suite/Query ID gi41327737refNM-005228.3. Available at: http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Get&VIEW-RESULTS= FromHome&RID=RN2S8U9801S&UNIQ-OBJ-NAME=A-SearchResults-1Py9Hs-2QPD- DRWwd15E2vW-GTKmF-Qw7Ss&QUERY-INDEX=0 [last accessed 01.03.11].
28. F. Ozcan, P. Klein, M.A. Lemmon, and J. Schlessinger On the nature of low- and high-affinity EGF receptors on living cells Proceedings of the National Academy of Sciences of United States of America 103 2006 5735 5740
29. R. Perez, A. Pascual, A. Macías, and A. Lage Epidermal growth factor receptors in human breast cancer Breast Cancer Research and Treatment 4 1984 189 193 (Pubitemid 14047954)
30. T.R. Shockley, K. Lin, C. Sung, J.A. Nagy, R.G. Tompkins, and R.L. Dedrick Quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels Cancer Research 52 1992 357 366
31. H. Schneider, and R.K. Miller Receptor-mediated uptake and transport in the human placenta International Journal of Develoment Biology 54 2010 367 375
32. J. Spicer Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience Current Opinion in Molecular Therapeutics 7 2005 182 191 (Pubitemid 40514689)
33. J. Stephenson Researchers describe findings for targeted cancer therapies [news] Journal of the American Medical Association 284 2000 293 295
34. X. Su, M.E. Lacouture, Y. Jia, and S. Wu Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis Oncology 77 2009 124 133
35. A. Talavera, R. Friemann, S. Gómez-Puerta, C. Martinez-Fleites, G. Garrido, and A. Rabasa Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation Cancer Research 69 2009 5851 5859
36. Tikhomirov I, Garrido G, Yang E, Sherman I, Pérez R. Bivalent binding properties of epidermal growth factor receptor (EGFR) targeted monoclonal antibodies: factors contributing to differences in observed clinical profiles. AACR Cancer Clinical Trials and Personalized Medicine 2008 (abstract A36). Available at: http://www.ymbiosciences.com/upload-files/poster-nimo-AACR- Translational-Med-2008.pdf [last accessed 22.06.09].
37. K. Tsaioun, and M. Jacewicz De-risking drug discovery with ADDME - avoiding drug development mistakes early ATLA 37 S1 2009 47 55
38. A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, and J.M. Schlaeppi Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Research 1 2001 5090 5101 (Pubitemid 32681540)